CHISON MEDICAL(SH:688358)2025-04-24 14:00Dividend Distribution - The company plans to distribute a cash dividend of 10 RMB per 10 shares, totaling approximately 111.87 million RMB, which represents 79.62% of the net profit attributable to shareholders for the year[5]. - The profit distribution plan has been approved by the board and will be submitted for shareholder approval at the 2024 annual general meeting[6]. - The total number of employees in the parent company and major subsidiaries is 537, with 186 in technical roles and 124 in sales[164]. - The cumulative cash dividend over the last three accounting years amounts to 279,861,731.30 RMB, with an average net profit of 130,942,887.15 RMB, resulting in a cash dividend ratio of 213.73%[178]. - The company has a cash dividend policy that prioritizes stable returns to shareholders while considering long-term growth and major investment plans[171]. Financial Performance - The company reported a revenue increase of 15% in 2024 compared to 2023, reaching a total of 500 million RMB[22]. - The company's operating revenue for 2024 was approximately ¥468.70 million, a decrease of 3.13% compared to ¥483.84 million in 2023[24]. - Net profit attributable to shareholders was approximately ¥140.51 million, down 4.08% from ¥146.48 million in the previous year[24]. - The net cash flow from operating activities increased significantly by 63.76% to approximately ¥140.68 million, compared to ¥85.91 million in 2023[24]. - The company's total assets reached approximately ¥1.60 billion, reflecting a growth of 4.89% from ¥1.52 billion at the end of 2023[24]. Research and Development - Research and development expenses increased by 10% in 2024, reflecting the company's commitment to innovation and new technology[22]. - The R&D investment as a percentage of operating revenue increased to 16.99%, up from 15.93% in the previous year[25]. - The company invested CNY 79.63 million in R&D, accounting for 16.99% of its revenue, and received 48 new patent authorizations, including 30 invention patents[34]. - The company has accumulated a total of 61 core technologies, focusing on continuous R&D investment to drive innovation in ultrasound medical imaging equipment[76]. - The company has introduced 10 new core technologies during the reporting period, enhancing portable ultrasound and AI ultrasound capabilities[75]. Market Position and Strategy - The company achieved a market share of 15% in the domestic ultrasound device market, positioning itself as a key player[22]. - The company is exploring potential acquisitions to enhance its product portfolio and market presence, with a focus on companies in the medical imaging sector[22]. - The company aims to become a global leader in specialized ultrasound by focusing on high-end color ultrasound, portable devices, and AI integration[133]. - The company has established a nationwide sales network covering over 30 provinces and regions in China, with significant growth potential in the domestic market due to its differentiated technology and international quality standards[63]. - The company is actively involved in the development of AI-assisted diagnostic technologies, enhancing the capabilities of its medical imaging devices[65]. Corporate Governance - The company has established a governance structure that ensures independence and coordination among the shareholders' meeting, board of directors, and management[141]. - The company has not reported any issues regarding independence or operational capability concerning its controlling shareholders[141]. - The board of directors includes members with extensive experience, such as the chairman and general manager, who has held the position since August 2023[145]. - The company has maintained a stable shareholding structure, with no changes in the number of shares held by directors during the reporting period[145]. - The company has established a remuneration and assessment committee to draft remuneration proposals for senior management[153]. Risk Management - The company has provided a detailed risk analysis regarding potential operational risks in the report[3]. - The company is facing risks related to product development failures due to the complexity of ultrasound technology[89]. - There is a risk of technology leakage that could negatively impact the company's competitive advantage[91]. - The company has not reported any significant risk issues reported by the supervisory board during the reporting period[163]. - The company has established a unified management process for subsidiaries to enhance operational efficiency and risk management[190]. Social Responsibility and ESG - The company emphasizes the importance of ESG practices, integrating sustainable development into daily operations and strategic decisions[193]. - The company actively participates in social responsibility initiatives, including medical assistance programs[192]. - The company has received ESG ratings of BB from Wind and Huazheng, and BBB from Zhidin[198]. - The company integrates green energy-saving design concepts into its product development, aiming to reduce energy costs and carbon emissions[197]. - The company has implemented strict waste classification, storage, and processing procedures to enhance recycling rates and reduce secondary pollution[197].